

Our Position on Global Access

At Vertex, we research, discover and develop innovative medicines for serious diseases. To develop these medicines, we invest significantly in research and development, with more than 70% of operating expenses and three out of five employees dedicated to that purpose.

Our aim is for our medicines to be accessible to as many patients as possible around the world. Access to medicines is dependent on multiple factors and requires many stakeholders to work together for the benefit of patients. This is especially true for cystic fibrosis and other serious chronic diseases where patients need sustainable and reliable access to treatment and specialist care for life. That is why we work with government agencies, policymakers, payors, patient advocacy organizations and health insurers on identifying and securing pathways to access.

As a result of these collaborative efforts, patients on five continents have access to our medicines through a range of routes, including fully reimbursed commercial access, individual named patient sales and compassionate use.

We have made significant progress securing reimbursed commercial access to our medicines globally and our cystic fibrosis medicines are currently approved and reimbursed in more than 25 countries globally. To this end, Vertex provides flexible and creative pricing solutions around the world. In some countries where our medicines are not funded or reimbursed, access is provided through individual named patient sales.

We've also established compassionate use programs for our CF medicines in countries where there is a path for sustainable access to help those who are critically ill and serve as a bridge to approval and reimbursement. We evaluate all requests in a fair and equitable manner and through this program we have provided access to treatment for thousands of patients globally.

We know there is more work to be done. Access barriers are complex, and partnerships and collaborations are critical to this work. We remain committed to working in partnership with all relevant stakeholders to make our medicines accessible to more patients around the world.